title: Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
abstract: BACKGROUND
  Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients. To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens.
  
  
  RESULTS
  This was a prospective, 16-week double-blind placebo-controlled randomized multicenter study in 171 obese hypertensive patients. After a 2-week run-in period, patients receiving 1 of the 3 antihypertensive combination therapies (felodipine 5 mg/ramipril 5 mg [n=57], verapamil 180 mg/trandolapril 2 mg [n=55], or metoprolol succinate 95 mg/hydrochlorothiazide 12.5 mg [metoprolol/hydrochlorothiazide; n=59]) were assigned randomly to sibutramine (15 mg) or placebo. Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment. Sibutramine-induced weight loss and reduction of visceral obesity were markedly attenuated in the metoprolol/hydrochlorothiazide group compared with the other groups. Consistently, improvement in glucose tolerance and hypertriglyceridemia by sibutramine was abrogated in the cohort treated with metoprolol/hydrochlorothiazide compared with the other groups.
  
  
  CONCLUSIONS
  The present study demonstrates for the first time that an antihypertensive combination therapy regimen with angiotensin-converting enzyme inhibitors and calcium channel blockers is more advantageous than a beta-blocker/diuretic-based regimen in supporting the weight-reducing actions and concomitant metabolic changes induced by sibutramine in obese hypertensive patients. These data may help to develop future comprehensive treatment strategies and guidelines for this high-risk patient population.
authors.affiliation: Department of Medicine, Outpatient Clinic, CCM, Charité-Universitätsmedizin Berlin, Luisenstrasse 11-13, 10117 Berlin, Germany. juergen.scholze@charite.de
authors.forename: Jürgen
authors.initials: J
authors.lastname: Scholze
authors.forename: Elmar
authors.initials: E
authors.lastname: Grimm
authors.forename: Dana
authors.initials: D
authors.lastname: Herrmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Unger
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kintscher
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000627:therapeutic use*; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015736:Felodipine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008790:Metoprolol / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D017257:Ramipril / Q000627:therapeutic use; D016896:Treatment Outcome; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D007211:Indoles; D006852:Hydrochlorothiazide; C052035:trandolapril; D014700:Verapamil; D008790:Metoprolol; D017257:Ramipril; D015736:Felodipine; C058254:sibutramine